SMO and colitis: Conversely, activation of the pathway in stroma by partial Ptch1 loss or treatment with the SMO agonist SAG21k [157] ameliorated the DSS-induced colitis with increased IL-10 expression and increased CD4+ Foxp3+ regulatory T cells [78].